Figure 4

TERT enhances cisplatin-resistance in osteosarcoma cells via promoting glutathione antioxidant defense system to reduce ROS level. (A) Transfected osteosarcoma cells were exposed to 5 μmol/L of cisplatin for 24 hours following which cellular ROS was assessed using the probe DCHF-DA. (B) Transfected osteosarcoma cells were treated with 5 μmol/L of cisplatin from 0 to 6 hours following which intracellular GSH/GSSG ratio was computed. (C) Transfected osteosarcoma cells were used to prepare the sample for the GPx and GR activity assay, and the fold difference was calculated. Data shown are mean ± S.D. Student t test was performed to evaluate the difference *P < 0.05.